Compare Invesco S&P 500 Momentum ETF (SPMO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

SPMO trades at $150.47, up 0.5% with a bullish technical outlook supported by strong moving average signals. The ETF has delivered exceptional performance, averaging 37% annual returns over three years according to The Motley Fool (2026-09-06). Recent momentum factor strength and concentrated tech exposure drive its market-beating track record, though this introduces higher volatility during sector rotations.

The outlook remains positive with structural momentum advantages and lower drawdowns than the S&P 500. Key risks include concentrated technology sector exposure and sensitivity to market rotations. Analyst sentiment leans bullish with multiple buy recommendations citing the ETF's rules-based momentum strategy and cost efficiency at 0.13% expense ratio.

XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.

Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.